Physician profile

Majed Mouded

Endocrinology, Diabetes & Metabolism · Fall River, MA

NPI 1346248531

$2,598.55

in general payments reported to CMS, 2019-2025

30 companies · none reported in 2025

See the full distribution for Endocrinology, Diabetes & Metabolism

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $445.60 2019-2021
Pfizer INC. $306.65 2019-2020
Amgen INC. $267.64 2019
Sanofi-Aventis U.S. LLC $198.49 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $173.27 2019-2020
Glaxosmithkline, LLC. $166.32 2019-2020
Amarin Pharma, INC. $163.89 2019-2020
Takeda Pharmaceuticals U.S.A., INC. $94.62 2019-2020
Janssen Pharmaceuticals, INC $77.30 2019-2020
Shire North American Group INC $76.89 2019
Novo Nordisk INC $74.10 2019-2020
Merck Sharp & Dohme LLC $63.40 2019-2020
Mylan Specialty L.P. $58.05 2019-2020
Abbott Laboratories $53.31 2019-2020
Regeneron Healthcare Solutions, INC. $49.11 2019
Show all 30 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Majed Mouded

$2,598.55

in general payments reported 2019-2025

Years
2019-2021
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/152070/majed-mouded

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.